Screener
Amneal Pharmaceuticals, Inc. AMRX Gross Profit
Gross Profit at other companies
Segments
By segment
Other financials
Where this comes from
Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net revenue | $796,197 | $724,508 | $1,518,716 | $1,419,928 |
| Cost of goods sold | 461,689 | 438,255 | 864,095 | 877,784 |
| Gross profit | 334,508 | 286,253 | 654,621 | 542,144 |
| Selling, general and administrative | 148,722 | 124,266 | 287,582 | 242,554 |
| Research and development | 39,017 | 47,964 | 77,400 | 88,004 |
| Intellectual property legal development expenses | 2,087 | 2,017 | 3,629 | 3,784 |
| Acquisition costs | 7,600 | — | 12,753 | — |
| Restructuring and other charges | 554 | 1,024 | 1,204 | 1,595 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s gross profit?
- Amneal Pharmaceuticals, Inc. (AMRX) reported gross profit of $334.51M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s gross profit changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s gross profit increased by 16.9% year-over-year, from $286.25M to $334.51M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s gross profit?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s gross profit has grown at a 9.7% compound annual growth rate (CAGR), from $768.97M to $1.11B.
- What does gross profit mean?
- Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.
Ask your AI about Amneal Pharmaceuticals, Inc.'s gross profit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude